Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, respectively. It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
It is also indicated as the maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma (UC), which has not progressed with first-line platinum-containing chemotherapy. In the US, avelumab is also indicated to treat locally advanced or metastatic UC with disease progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Avelumab is indicated, in combination with axitinib, for the first-line treatment of advanced renal cell carcinoma (RCC).
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT02584634
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston Inc (OCB), Boston, Massachusetts, United States
🇯🇵Aichi cancer center central hospital, Nagoya, Aichi, Japan
🇪🇸Hospital Universitari de la Vall d'Hebron, Barcelona, Spain
Avelumab in First-line NSCLC (JAVELIN Lung 100)
- Conditions
- First Line Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2025-01-31
- Target Recruit Count
- 1214
- Registration Number
- NCT02576574
- Locations
- 🇧🇪
A.Z. Klina, Brasschaat, Belgium
🇦🇺Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇺🇸Arizona Center for Cancer Care, Surprise, Arizona, United States
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 409
- Registration Number
- NCT02554812
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇦🇺The Mater Hospital, North Sydney, New South Wales, Australia
🇺🇸Mount Sinai Comprehensive Cancer Center - Aventura, Aventura, Florida, United States
A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
- Conditions
- Renal Cell Cancer
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 55
- Registration Number
- NCT02493751
- Locations
- 🇯🇵
Kindai University Hospital, Osakasayama, Osaka, Japan
🇯🇵Keio University Hospital, Shinjuku-ku, Tokyo, Japan
🇺🇸Scottsdale Healthcare Hospitals d/b/a HonorHealth, Scottsdale, Arizona, United States
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2020-08-03
- Target Recruit Count
- 792
- Registration Number
- NCT02395172
- Locations
- 🇨🇴
Hemato Oncologos S.A., Cali, Colombia
🇺🇸Healing Hands Oncology and Medical Care, Lawndale, California, United States
🇦🇷Hospital Universitario Austral, Pilar, Argentina
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 65
- Registration Number
- NCT02349633
- Locations
- 🇺🇸
UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2024-03-13
- Target Recruit Count
- 204
- Registration Number
- NCT02155647
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
🇮🇹Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 57
- Registration Number
- NCT01943461
- Locations
- 🇩🇪
Research site, Darmstadt, Germany
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2021-12-20
- Target Recruit Count
- 1756
- Registration Number
- NCT01772004
- Locations
- 🇺🇸
Cancer Treatment Centers of America - Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸Highlands Oncology Group, Rogers, Arkansas, United States
🇺🇸California Cancer Associates for Research & Excellence, Inc, Encinitas, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.